These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 8167213)

  • 21. Psychophamacological treatment.
    Marriott P
    Schizophr Bull; 1976; 2(4):505-6. PubMed ID: 1019592
    [No Abstract]   [Full Text] [Related]  

  • 22. Predictors of the course of tardive dyskinesia in patients receiving neuroleptics.
    Bergen J; Kitchin R; Berry G
    Biol Psychiatry; 1992 Oct; 32(7):580-94. PubMed ID: 1360260
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Haloperidol decanoate as a replacement for maintenance therapy with intramuscular fluphenazine decanoate in schizophrenia and other chronic psychoses.
    Roose K
    Acta Psychiatr Belg; 1982; 82(2):216-23. PubMed ID: 7180558
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapy with injectable fluphenazines.
    Ayd FJ
    Curr Psychiatr Ther; 1976; 16():177-89. PubMed ID: 991628
    [No Abstract]   [Full Text] [Related]  

  • 25. [Tardive dystonia--a case report on therapy and metaphylaxis].
    Genz A
    Psychiatr Neurol Med Psychol (Leipz); 1988 May; 40(5):264-8. PubMed ID: 2905065
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A double-blind dose-reduction trial of fluphenazine decanoate for chronic, unstable schizophrenic patients.
    Inderbitzin LB; Lewine RR; Scheller-Gilkey G; Swofford CD; Egan GJ; Gloersen BA; Vidanagama BP; Waternaux C
    Am J Psychiatry; 1994 Dec; 151(12):1753-9. PubMed ID: 7977881
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Evaluation of the incidence of tardive dyskinesias in 3 groups of patients treated with different neuroleptics].
    Barcia D; Pozo P; Ruiz ME; Forcadell F; Morcillo L; Soria JM; Carrasco E
    Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1987; 15(1):25-8. PubMed ID: 3577874
    [No Abstract]   [Full Text] [Related]  

  • 28. Tardive dyskinesia and current dose of neuroleptic drugs.
    Kolakowska T; Williams AO; Ardern M
    Arch Gen Psychiatry; 1986 Jun; 43(6):614. PubMed ID: 2871820
    [No Abstract]   [Full Text] [Related]  

  • 29. Tardive dyskinesia. Evaluation in a nurse managed prolixin program.
    Scrak BM; Greenstein RA
    J Psychosoc Nurs Ment Health Serv; 1986 May; 24(5):10-4. PubMed ID: 2872329
    [No Abstract]   [Full Text] [Related]  

  • 30. Discontinuation of oral and depot fluphenazine in schizophrenic patients after one year of continuous medication: a controlled study.
    Levine J; Schooler NR; Severe J; Escobar J; Gelenberg A; Mandel M; Sovner R; Steinbook R
    Adv Biochem Psychopharmacol; 1980; 24():483-93. PubMed ID: 6996445
    [No Abstract]   [Full Text] [Related]  

  • 31. Drug history and tardive dyskinesia.
    Smith RC; Strizich M; Klass D
    Am J Psychiatry; 1978 Nov; 135(11):1402-3. PubMed ID: 30289
    [No Abstract]   [Full Text] [Related]  

  • 32. Follow-up study of 281 schizophrenic patients treated with high dosage fluphenazine decanoate.
    Steiner S; Nagy C
    Int Pharmacopsychiatry; 1981; 16(3):184-92. PubMed ID: 7319750
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fluphenazine decanoate. Its steady-state pharmacologic profile and relationship to tardive dyskinesia.
    Glazer WM
    Schizophr Res; 1988; 1(6):425-9. PubMed ID: 3154530
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Facial dyskinesia: a 16-year follow-up study.
    McClelland HA; Metcalfe AV; Kerr TA; Dutta D; Watson P
    Br J Psychiatry; 1991 May; 158():691-6. PubMed ID: 1677601
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Results of the use of fluphenazine in a depot preparation].
    Marcjan K; Pietruszewska I; Wolak E
    Psychiatr Neurol Med Psychol Beih; 1975; 20-21():176-82. PubMed ID: 829619
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tardive dystonia. The benefits of time.
    Cooper SJ; Doherty MM; King DJ
    Br J Psychiatry; 1989 Jul; 155():113-5. PubMed ID: 2691000
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Movement disorders in patients treated with long-acting injectable antipsychotic drugs.
    Bransgrove LL; Kelly MW
    Am J Hosp Pharm; 1994 Apr; 51(7):895-9. PubMed ID: 7912473
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized clinical trial of haloperidol decanoate and fluphenazine decanoate in the outpatient treatment of schizophrenia.
    Chouinard G; Annable L; Campbell W
    J Clin Psychopharmacol; 1989 Aug; 9(4):247-53. PubMed ID: 2570086
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tardive dyskinesia in psychiatric outpatients: a study of prevalence and association with demographic, clinical, and drug history variables.
    Mukherjee S; Rosen AM; Cardenas C; Varia V; Olarte S
    Arch Gen Psychiatry; 1982 Apr; 39(4):466-9. PubMed ID: 6121547
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Spiramycin-associated acute dystonia during neuroleptic treatment.
    Benazzi F
    Can J Psychiatry; 1997 Aug; 42(6):665-6. PubMed ID: 9288434
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.